Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Cholesterol Guidelines Follow Long History Of Failed Outcomes Trials

Executive Summary

The cardiology community is increasingly questioning the value of adding on a variety of lipid therapies to treatment with highly effective statins, based on accumulating evidence of the lack of value of affecting cholesterol parameters other than LDL.

Advertisement

Related Content

Panel To Weigh Amarin’s Expanded Vascepa Use Given Clinical Outcome Concerns
Dalcetrapib Failure Raises Yet More Questions On Value Of Tinkering With HDL Cholesterol
Merck, Lilly Vow To Press On With CETP, Despite Dalcetrapib Disaster
Big Pharma’s Gamble On HDL Hypothesis
More Disheartening News For Abbott Cholesterol Franchise: Niaspan/Statin Study Halted Due To Lack Of Added Benefit
AstraZeneca And Abbott Pull The Plug On Cardio Combination Drug
Abbott's Fibrate Franchise Will Likely Remain Limited To High-Risk Patients After ACCORD
New Look At Ezetimibe Fails To Confirm Vytorin Cancer Signal
No Surprises From ENHANCE At ACC Mean Vytorin Hopes Hang On IMPROVE-IT
Pfizer’s Lipitor Extension Shot Down By Failure Of Torcetrapib Silver Bullet

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS055780

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel